Prospective Evaluation of Clinically Relevant Type B Hyperlactatemia in Dogs with Cancer

Background: Cancer is considered a cause of type B hyperlactatemia in dogs. However, studies evaluating cancer as a cause of clinically relevant type B hyperlactatemia (>2.5 mmol/L) are lacking. Cancer cells have a higher lactate production because of increased aerobic glycolysis, known as the “W...

Full description

Saved in:
Bibliographic Details
Published inJournal of veterinary internal medicine Vol. 24; no. 6; pp. 1458 - 1461
Main Authors Touret, M, Boysen, S.R, Nadeau, M.E
Format Journal Article
LanguageEnglish
Published Malden, USA J.B. Lippincott 01.11.2010
Blackwell Publishing Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: Cancer is considered a cause of type B hyperlactatemia in dogs. However, studies evaluating cancer as a cause of clinically relevant type B hyperlactatemia (>2.5 mmol/L) are lacking. Cancer cells have a higher lactate production because of increased aerobic glycolysis, known as the “Warburg effect.” The mechanisms through which aerobic glycolysis occurs are not well elucidated, but neoplasia may cause type B hyperlactatemia via this process. Objectives: To determine if malignant tumors of dogs are associated with clinically relevant type B hyperlactatemia (>2.5 mmol/L). Animals: Thirty-seven client-owned dogs with malignant tumors: 22 with hematopoietic and 15 with solid tumors. Methods: Histology was used to confirm the diagnosis (cytology was considered adequate for diagnosis of lymphoma). Confounding conditions associated with hyperlactatemia were excluded. Lactate measurements were immediately performed on free-flow jugular whole blood samples using the LactatePro analyzer. Results: All dogs had lactate concentrations <2.5 mmol/L. Mean blood lactate concentration was 1.09 mmol/L. Mean blood lactate concentrations for solid and hematopoietic tumors were 0.95 and 1.19 mmol/L, respectively. Dogs with lymphoma (n = 18) had a mean blood lactate concentration of 1.15 mmol/L. Conclusions: Malignant tumors were not considered a cause of clinically relevant type B hyperlactatemia. Therefore, cancer-related type B hyperlactatemia in dogs is uncommon, and hyperlactatemia should prompt careful investigation for causes other than cancer.
Bibliography:http://dx.doi.org/.1111/j.1939-1676.2010.0626.x
istex:9F064A122DDC95530F09F159DD23857CF164F5D8
ark:/67375/WNG-J5D45M3B-V
ArticleID:JVIM626
This study was done at the Centre Hospitalier Universitaire Vétérinaire, Université de Montréal, Saint‐Hyacinthe, QC, Canada. This work has been presented as an abstract at the Annual ACVIM Forum, June 2009, Montreal, Canada.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0891-6640
1939-1676
DOI:10.1111/j.1939-1676.2010.0626.x